A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Withdrawn before enrolling · Phase 4

Conditions studied: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

In brief

The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D) The study will last about 6 months.

Key facts

Study ID

NCT04864977

Run by

Eli Lilly and Company

People needed

0

Starts

2021-08-16

Expected to finish

2022-06-06

Last updated by the study team

2021-08-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults with type 2 diabetes as diagnosed by endocrinologist
• No insulin over past 3 months
• Inadequate glycemic control with A1c ≥8.0% at or within 1 month prior to screening visit
• No history of diabetic ketoacidosis (DKA) or severe hypoglycemia leading to mental status change in the past 6 months
• Willingness and ability to follow the protocol including willingness to commence basal insulin, wear CGM, and communicate with healthcare provider.

You may not qualify if…

• Contraindication to use of insulin glargine (e.g., allergy)
• Impaired recognition of hypoglycemia by the participant (as judged by the investigator)

Where it is running

• Boston Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.